Literature DB >> 7416556

Aortobronchial fistula: keys to successful management.

S L Demeter, E M Cordasco.   

Abstract

Aortobronchial fistula is a rare but highly lethal condition. If diagnosed, its survival rates are greater than 80%; if not, the condition is uniformly fatal with death most commonly due to massive hemoptysis. A review of the world's literature and an illustrated case are presented. A total of 30 cases have been described, but the published incidence may be low. Of the cases presented to sufficient detail for analysis, 92% (23 of 25) were associated with an aneurysm of the thoracic aorta. The most consistent symptom was hemoptysis (22 of 23, 96%), especially massive hemoptysis (15 of 19, 79%). Plain chest radiographs demonstrated an aneurysm in 46% (6 of 13 evaluable cases). Either an aneurysm on the chest x-ray or massive hemoptysis, or both were seen in 94% of cases (16 of 17). The most rewarding test (in 5 of 7, 71%) was the thoracic aortogram. Surgical correction was followed by an 82% survival rate (9 of 11). Untreated, the eventual mortality was 100%, although one patient died as late as 6 months after the initial presentation with massive hemoptysis.

Entities:  

Mesh:

Year:  1980        PMID: 7416556     DOI: 10.1177/000331978003100607

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

1.  In situ replacement of the thoracic aorta using an equine pericardial roll graft for an aortobronchial fistula due to aortic rupture.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto; Kazuyuki Ishibashi; Yoshifumi Chida; Yoshihiro Minamiya; Hiroshi Nanjo
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-09-24

2.  A tuberculous pseudoaneurysm of the thoracic aorta presenting as massive hemoptysis--a case of successful surgical treatment.

Authors:  J Ogawa; H Inoue; H Inoue; S Koide; S Kawada; A Shohtsu
Journal:  Jpn J Surg       Date:  1990-01

3.  Aortobronchial fistula following aortic valve surgery.

Authors:  M Ninan; S Hunter; D J Parker
Journal:  J R Soc Med       Date:  1994-09       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.